Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice
Doran Ksienski, Elaine S Wai, Nicole Croteau, et al.
Health Science Reports
|
July 23, 2025
Health Insurance Payer Status Is Associated With Frailty in a Surgical Patient Population: A Retrospective Case Series
David Fenton, Johnathan R Kent, Rachel Nordgren, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 28, 2009
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer
Thomas J Lynch, David Fenton, Vera Hirsh, et al.
Translational Lung Cancer Research
|
February 11, 2021
Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab
Doran Ksienski, Elaine S Wai, Deepu Alex, et al.
Journal of Public Health Research
|
June 13, 2024
The association between neighborhood disadvantage and frailty: A retrospective case series
David Fenton, Amani Allen, Johnathan R Kent, et al.
JTCVS Open
|
January 11, 2024
Racial differences in phenotypic frailty assessment among general thoracic surgery patients
Johnathan R Kent, Emily M Silver, Rachel Nordgren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2006
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Andrea Bezjak, Dongsheng Tu, Lesley Seymour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study
Glenwood D Goss, Andrew Arnold, Frances A Shepherd, et al.
NPJ Breast Cancer
|
January 5, 2024
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment
Elena Zaikova, Brian Y C Cheng, Viviana Cerda, et al.
JEMS : a Journal of Emergency Medical Services
|
December 16, 2006
Countering chemical agents
Richard C Dart, Armando Bevelaqua, Craig DeAtley, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice
Doran Ksienski, Elaine S Wai, Nicole Croteau, et al.
Health Science Reports
|
July 23, 2025
Health Insurance Payer Status Is Associated With Frailty in a Surgical Patient Population: A Retrospective Case Series
David Fenton, Johnathan R Kent, Rachel Nordgren, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 28, 2009
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer
Thomas J Lynch, David Fenton, Vera Hirsh, et al.
Translational Lung Cancer Research
|
February 11, 2021
Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab
Doran Ksienski, Elaine S Wai, Deepu Alex, et al.
Journal of Public Health Research
|
June 13, 2024
The association between neighborhood disadvantage and frailty: A retrospective case series
David Fenton, Amani Allen, Johnathan R Kent, et al.
JTCVS Open
|
January 11, 2024
Racial differences in phenotypic frailty assessment among general thoracic surgery patients
Johnathan R Kent, Emily M Silver, Rachel Nordgren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2006
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Andrea Bezjak, Dongsheng Tu, Lesley Seymour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study
Glenwood D Goss, Andrew Arnold, Frances A Shepherd, et al.
NPJ Breast Cancer
|
January 5, 2024
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment
Elena Zaikova, Brian Y C Cheng, Viviana Cerda, et al.
JEMS : a Journal of Emergency Medical Services
|
December 16, 2006
Countering chemical agents
Richard C Dart, Armando Bevelaqua, Craig DeAtley, et al.
Page
of 6